



## Actinogen Medical Company Profile

### Overview

Actinogen Medical (ASX: ACW) is an ASX-listed biotech company focused on innovative approaches to treating cognitive decline that occurs in chronic neurodegenerative and metabolic diseases. Xanamem™, Actinogen Medical's lead candidate drug, blocks excess production of the stress hormone cortisol in the brain. There is growing evidence that chronic stress and excess cortisol leads to changes in the brain affecting memory, and to the development of amyloid plaques and neural death – all hallmarks of Alzheimer's disease. In 2016, the Company initiated XanADu, a Phase II efficacy and safety trial of Xanamem™ in mild Alzheimer's disease.

### About Xanamem™

Xanamem™ is being developed as a promising new therapy for Alzheimer's disease, a condition with a multibillion dollar market potential. In the US alone, the cost of managing Alzheimer's disease in 2013 was estimated to be US\$250bn, and is set to increase to US\$1 trillion by 2050, outstripping the treatment costs of all other diseases. Alzheimer's disease is now the leading cause of death in the UK and second only to ischaemic heart disease in Australia. Xanamem™'s novel mechanism of action sets it apart from other Alzheimer's treatments. It works by blocking the excess production of cortisol - the stress

### Speaker Profile

#### Dr Bill Ketelbey, CEO & Managing Director



Dr Ketelbey has more than 30 years' experience in the healthcare, biotech and pharmaceutical industries, including senior medical and management roles in the Asia Pacific Region with global pharmaceutical company Pfizer.

Dr Ketelbey has a solid track record of product development over his years in the industry leading to the successful registration, launch and commercialisation of numerous market leading medicines in a broad range of therapeutic areas, including in Alzheimer's Disease. Dr Ketelbey led the local clinical development, and was involved in the commercialisation, of Aricept™ (donepezil), the market-leading Alzheimer's disease therapy.

Dr Ketelbey is a medical graduate from the University of the Witwatersrand, South Africa and a Fellow of the Faculty of Pharmaceutical Physicians from the Royal College of Physicians in the United Kingdom. He also has an MBA from Macquarie Graduate School of Management, Australia, and is a Graduate of the Australian Institute of Company Directors.